DDIT4L: A Potential Drug Target for Neurodegenerative and Psychiatric Disorders

Target Name: DDIT4L

NCBI ID: G115265

DDIT4L

DDIT4L: A Potential Drug Target for Neurodegenerative and Psychiatric Disorders

DDIT4L (doublecortin-related protein 4-like) is a protein that has been identified as a potential drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and psychiatric disorders. Its unique structure and function have made it an attractive target for researchers to investigate.

Structure and Function

DDIT4L is a 22-kDa protein that is expressed in various tissues, including the brain, pancreas, and heart. It has a molecular weight of 41 kDa and a calculated pI of 6.3. The protein is composed of two distinct domains: a N-terminal domain with a predicted transmembrane segment and a C-terminal domain that contains a unique protein-coding region.

The N-terminal domain is composed of a single alpha-helix and a beta-sheet, which is characteristic of the protein transmembrane domain. The beta-sheet contains several parallel beta-strands that are responsible for the protein's stability and interactions with other molecules.

The C-terminal domain is characterized by a unique arrangement of amino acids that gives the protein its unique structure and function. The C-terminal domain contains a variable region, which is responsible for the protein's unique structure and function.

The variable region contains several distinct regions, including an extended amino acid region (EAR) that is involved in protein-protein interactions and a short amino acid region (SAR) that is involved in the protein's stability. The EAR and SAR regions are connected by a flexible loop, which allows the protein to undergo changes in conformation.

The protein also has a unique post-translational modification (PTM) at its C-terminus. Specifically, it has a N-acetylation of its lysine residue, which is a common PTM for proteins that play a role in neurotransmitter signaling.

Disease Modeling

The unique structure and function of DDIT4L have made it an attractive target for drug development. Its potential drug targets include neurodegenerative diseases, psychiatric disorders, and cancer.

Neurodegenerative Diseases

DDIT4L has been shown to be involved in the development and progression of several neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. Its involvement in these diseases has been attributed to its role in the production of neurotransmitters, such as dopamine and serotonin, which are involved in the regulation of neural function.

In addition, the protein has also been shown to play a role in the regulation of neurotransmitter receptor function, which is a critical component of neurotransmission.

Psychiatric Disorders

DDIT4L has also been shown to be involved in the development and progression of several psychiatric disorders, including depression, anxiety, and schizophrenia. Its involvement in these disorders has been attributed to its role in the regulation of neurotransmitter function and the development of neurotransmitter imbalances.

In addition, the protein has also been shown to play a role in the regulation of brain-derived neurotrophic factor (BDNF) signaling, which is involved in the maintenance of brain function and is often impaired in psychiatric disorders.

Cancer

DDIT4L has also been shown to be involved in the development and progression of several types of cancer, including breast, lung, and ovarian cancer. Its involvement in these diseases has been attributed to its role in the regulation of cell signaling pathways, including the regulation of cell proliferation and the production of angiogenesis-promoting factors.

In addition, the protein has also been shown to play

Protein Name: DNA Damage Inducible Transcript 4 Like

Functions: Inhibits cell growth by regulating the TOR signaling pathway upstream of the TSC1-TSC2 complex and downstream of AKT1

The "DDIT4L Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DDIT4L comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets